What makes BioAgilytix an exciting place to work? We talk to Matthew Hoyle, our Associate Director, Global Marketing – whom is a BioAgilytix returning employee after spending 4 years in different business – to find out what drove him back to the company, and what programs he is spearheading now to make the worldwide pharma and biotech industry aware of the premier large molecule expertise available to them through BioAgilytix.
With innovative research driving pharmaceutical and biotech breakthroughs, industry progress is accelerating at a rapid pace. We've compiled some recent industry articles on the latest topics to share with you.
Cell-based bioassays are expected by health agencies as one of the release specification methods for potency assessments in the drug development process. We take a closer look at the inherent complexities that come with developing these assays under GMP, and ways they can be overcome.
Most bioanalytical methods for canonical small or large molecule drugs utilize ligand binding or LC–MS technology for pharmacokinetic (PK) assessments. CAR-T cell therapies involve administration of ‘living drugs’ capable of proliferation after infusion. This behavior is very different from conventional drug compounds, and the term ‘cellular kinetics’ was coined for in vivo ‘PK monitoring’ of both the expansion and persistence of the genetically engineered CAR-T cells.
We strive to foster an environment where our team members can continually grow within their role and within the company – not only upwards, but also into positions they come to find most suited to their unique skills and interests. In this Team Q&A session, we talk to Tatjana Ackermann, Quality Assurance Auditor, about her career path at BioAgilytix since starting in our European lab five years ago.
The first in-human in vivo clinical trial using CRISPR-Cas9 is now open for enrollment; we take a closer look at this genome editing technology to understand its promising benefits as well as the potential challenges of anti-Cas9 immunity.
In our latest Team Q&A, we talk to Janett Schwarz, Principal Investigator at BioAgilytix’s European headquarters, about how her role has evolved since joining our team – including how she came to be our resident expert on IgE antibody testing on the ImmunoCAP platform.
We're looking forward to participating in several upcoming bioanalytical conferences and events this fall, ranging from small-circle workshops to global, world-renowned industry forums.
Many great questions were asked by our audience during Dr. Afshin Safavi’s recent webinar on exploratory biomarker testing. We've compiled his answers those he didn’t have time to address during the live session.
In this Q&A session we talk with Eric Nesbit, Bioanalytical Project Manager/Scientist III at BioAgilytix, to learn more about what led him to leave his hometown of Maine for our headquarters in North Carolina, and why he recruited his sister to join our team as well.
